Amgen's Blincyto Is First Cancer Drug To Get Medicare Add-On Payments
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS agrees to provide new technology add-on payments for Amgen’s cancer drug for acute lymphoblastic leukemia after the company documents Blincyto’s uniqueness and its advantages over existing treatments.